Notice Regarding the Renaming of “Jeyou Pharmaceutical”|Jeyou Pharmaceuticals - Jeyou Pharmaceutical Technology Co., Ltd.

Notice Regarding the Renaming of “Jeyou Pharmaceutical”

2025.07.01

Dear Partners and Valued Customers:

Thanks to your continued trust and support for Jeyou Pharmaceuticals, we have been able to grow and advance rapidly.

To align with our strategic development needs, Shanghai Jiyu Pharmaceutical Technology Co., Ltd. officially changed its name to Shanghai Jeyou Pharmaceutical Technology Co., Ltd. on June 20, 2025.

Following this rebranding, we will continue to uphold our business philosophy of “Focus, Professionalism, Innovation, and Entrepreneurship.” We are committed to collaborating with our partners for mutual success, addressing unmet clinical needs, deepening our expertise in the pharmaceutical technology sector, and striving to deliver superior products and solutions to achieve high-quality development.

Shanghai Jeyou Pharmaceutical Technology Co., Ltd.

June 20, 2025

Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria

Jeyou Pharma and RAPT Announce Exclusive Licensing Agreement for a Novel Long-Acting IgE Antibody

Notice Regarding the Renaming of “Jeyou Pharmaceutical”

Trending News

JeYou Pharma's AR-NTD Inhibitor Clinical Trial Application Approved

Phase III clinical enrollment of anti-IgE monoclonal antibody independently developed by JeYou Medicine for chronic spontaneous urticaria (CSU) was completed ahead of schedule.

Application for initiation of clinical trials of JeYou Pharmaceuticals 'CDK4 inhibitor and CDK2-PROTAC drug candidate molecule